Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.
about
Molecules that target nucleophosmin for cancer treatment: an updateProtein Kinase CK2: A Targetable BCR-ABL Partner in Philadelphia Positive LeukemiasThe p53 transcriptional pathway is preserved in ATMmutated and NOTCH1mutated chronic lymphocytic leukemias.Targeting casein kinase II restores Ikaros tumor suppressor activity and demonstrates therapeutic efficacy in high-risk leukemia.Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma.Casein kinase 2 controls the survival of normal thymic and leukemic γδ T cells via promotion of AKT signaling.Casein kinases as potential therapeutic targets.Casein Kinase II (CK2), Glycogen Synthase Kinase-3 (GSK-3) and Ikaros mediated regulation of leukemia.Inhibition of protein kinase II (CK2) prevents induced signal transducer and activator of transcription (STAT) 1/3 and constitutive STAT3 activation.Protein Kinase CK2: Intricate Relationships within Regulatory Cellular Networks.Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones.BCR-ABL inactivates cytosolic PTEN through Casein Kinase II mediated tail phosphorylation.Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.Therapeutic targeting of CK2 in acute and chronic leukemias.
P2860
Q26750653-99AE0666-D40B-43E0-AC6E-8325C2C57D67Q26769590-99A27656-0C76-4F25-A332-5E8B3C736979Q35149661-4CD3AEA3-E890-44CF-BFD3-FB33DB710A20Q36143247-FCA530AC-71C8-4705-A483-F15F84A6181CQ36544222-F2806D0D-DF1A-4798-8789-0853D21B8FEBQ37710288-A6A14C8C-5487-4BB3-8716-E67497BE658FQ38632634-2F15F6FA-292C-4359-9EDB-FB05C3FE9698Q38721782-32C0A2DD-8B80-4263-B4DA-F8BF3BDC47E4Q39003208-1D768CFA-38A3-43BE-87D5-246AFE405DFFQ39168849-651C7A51-C9EE-41FE-A0DF-B1F93781FD87Q41056246-778066E1-7FFB-4914-8C94-8A1521819F3DQ41813901-38570218-3FE8-421A-BD9B-12A2F8E6FE9DQ42284390-470269E0-BFAA-4A77-B6E6-5F8712BF343DQ47677919-6AC68B7A-902D-4F94-A295-F2F1200CA9AB
P2860
Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Targeting chronic lymphocytic ...... l-permeable peptide inhibitor.
@en
type
label
Targeting chronic lymphocytic ...... l-permeable peptide inhibitor.
@en
prefLabel
Targeting chronic lymphocytic ...... l-permeable peptide inhibitor.
@en
P2093
P2860
P356
P1433
P1476
Targeting chronic lymphocytic ...... ll-permeable peptide inhibitor
@en
P2093
João T Barata
Maria G Silva
Silvio E Perea
Yasser Perera
P2860
P304
P356
10.18632/ONCOTARGET.1513
P407
P577
2014-01-01T00:00:00Z